Patrys cancer antibody synergistic in myeloma

Patrys (ASX:PAB) has said preclinical research into its PAT-SM6 anticancer candidate supports its ability to work synergistically with other drugs in multiple myeloma.

The research showing that the PAT-SM6 antibody works well with existing treatments such as Revlimid, Velcade and Dexamethasone is an important prerequisite of the product’s development as a treatment for multiple myeloma.

Studies in a mouse model of the disease suggest that PAT-SM6 is effective as a monotherapy but is also synergistic with double and triple combinations of drugs. Triple combinations were particularly effective at inhibiting the growth of multiple myeloma cells, with the most potent combination being PAT-SM6 plus Revlimid plus Dexamethasone.

“Showing that our antibody works in synergy with marketed multiple myeloma drugs is important and such information will help us in the design of future clinical trials,” Patrys CEO Dr Marie Roskrow said.

“There is no doubt that prospective partners ... will be looking for such data.”

As a monotherapy, PAT-SM6 was able to reduce tumour load by up to 54% and serum paraprotein levels by up to 48%, when compared to controls. The mice were given 6-8 doses over a 3- to 4-week period.

PAT-SM6 is a natural human antibody shown to bind to around 90% of tumours regardless of cancer type or progression.

It has shown particular promise in multiple myeloma, where it is in stage I/IIa trials, and in melanoma. The company concluded a phase I trial in melanoma last year. 

Patrys shares were trading 5.71% higher at $0.037 as of around 3 pm on Wednesday.